Locally advanced non-small cell lung cancer: current issues and recent trends

Alaswad, Moahmmed

doi:10.5603/rpor.a2023.0019

Cited by 3 publications

(2 citation statements)

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings suggest that for this population, PFS of the concurrent immunotherapy group was significantly longer than that of the consolidative immunotherapy group, especially among those who had a non-primary initial site of recurrence. The PACIFIC trial is the most widely recognized radioimmunotherapy combination therapy for NSCLC ( 12 ). The PACIFIC trial found that the use of durvalumab at the end of chemoradiotherapy provided robust and sustained OS compared to chemoradiotherapy alone (OS; 47.5 vs. 29.1 months; HR 0.72) and extensive PFS benefit (PFS: 16.9 vs. 5.9 months; HR 0.55), with 42.9% of patients remaining alive at 5 years ( 7 ).…”

Section: Discussionmentioning

confidence: 99%

A retrospective comparative cohort study: concurrent versus consolidative immunotherapy with chemoradiotherapy in EGFR- or ALK-negative unresectable stage III non-small cell lung cancer

Wu,

Guo,

Meng

et al. 2023

Transl Lung Cancer Res

View full text Add to dashboard Cite

Background The treatment of stage III non-small cell lung cancer (NSCLC) is very challenging because it is a heterogeneous group of diseases. This study was to investigative whether concurrent immunotherapy with chemoradiotherapy was associated with improved outcomes compared to consolidative immunotherapy following chemoradiotherapy in patients with unresectable stage III NSCLC, which may provide evidence-based medical evidence for the treatment of stage III NSCLC. Methods A total of 78 epidermal growth factor receptor or anaplastic lymphoma kinase (EGFR/ALK) negative patients from the clinical database of the shanghai pulmonary hospital with locally advanced unresectable NSCLC and we evaluated them for baseline clinical factors, follow-up. Patients underwent concurrent immunotherapy with chemoradiotherapy or consolidative immunotherapy after chemoradiotherapy. Patients were classified based on initial site of progression (primary versus non-primary site). The study endpoints were progression-free survival (PFS) and time to death or distant metastasis (TDDM). Cox proportional hazards analysis was used to assess the factors affecting PFS and TDDM. Results The median follow-up time for both groups was 26 months, and there was no significant difference in baseline clinical characteristics (P>0.05). The patients receiving concurrent immunotherapy (n=36) had a longer PFS than those receiving consolidative immunotherapy (n=42) (median 32.4 vs. 15.5 months; P<0.01). The TDDM was also longer in patients with concurrent immunotherapy than those with consolidative immunotherapy (median 57.3 vs. 31.0 months; P=0.01). Furthermore, in a subset of patients with initial site of progression at a non-primary-site, patients undergoing concurrent immunotherapy had longer PFS than those undergoing consolidative immunotherapy (median 22.7 vs. 11.9 months; P=0.03). Conclusions Concurrent immunotherapy with chemoradiotherapy may be associated with improved disease progression outcomes as compared to consolidative immunotherapy following chemoradiotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

A retrospective comparative cohort study: concurrent versus consolidative immunotherapy with chemoradiotherapy in EGFR- or ALK-negative unresectable stage III non-small cell lung cancer

Wu,

Guo,

Meng

et al. 2023

Transl Lung Cancer Res

View full text Add to dashboard Cite

show abstract

“…Furthermore, histologic diagnosis is another method that can be implemented if the patient is suspected to have lung cancer. In a significant number of lung cancer patients, the tumor cells metastasize to other organs, largely to lymph nodes, bones, adrenal glands, and the brain [ 17 , 18 , 19 , 20 ]. Notably, the tumor type and stages of the cancer are used to determine the prognosis and treatment options [ 21 , 22 ].…”

Section: Introductionmentioning

confidence: 99%

Therapeutic Implications of PTEN in Non-Small Cell Lung Cancer

Sirhan,

Alojair,

Thyagarajan

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Lung cancer remains one of the major human malignancies affecting both men and women worldwide, with non-small cell lung cancer (NSCLC) being the most prevalent type. Multiple mechanisms have been identified that favor tumor growth as well as impede the efficacy of therapeutic regimens in lung cancer patients. Among tumor suppressor genes that play critical roles in regulating cancer growth, the phosphatase and tensin homolog (PTEN) constitutes one of the important family members implicated in controlling various functional activities of tumor cells, including cell proliferation, apoptosis, angiogenesis, and metastasis. Notably, clinical studies have also documented that lung tumors having an impaired, mutated, or loss of PTEN are associated with low survival or high tumor recurrence rates. To that end, PTEN has been explored as a promising target for anti-cancer agents. Importantly, the ability of PTEN to crosstalk with several signaling pathways provides new approaches to devise effective treatment options for lung cancer treatment. The current review highlights the significance of PTEN and its implications in therapeutic approaches against NSCLC.

show abstract

EGFR-Targeted Therapies: A Literature Review

Sha,

Lee

2024

JCM

View full text Add to dashboard Cite

Lung cancer remains the leading cause of cancer death in the United States, underscoring the critical need to optimize treatment strategies. Compared to conventional treatments such as surgical resection, radiotherapy, chemotherapy, and immunotherapy, targeted therapy stands out for its higher selectivity and minimal adverse effects. Among these, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the most widely used in targeted therapy for non-small-cell lung cancer (NSCLC). In our paper, we will conduct a comprehensive review of current literature on EGFR TKIs to contribute to advancements in molecular genomics and the treatment of lung cancer.

show abstract

Locally advanced non-small cell lung cancer: current issues and recent trends

Cited by 3 publications

References 105 publications

A retrospective comparative cohort study: concurrent versus consolidative immunotherapy with chemoradiotherapy in EGFR- or ALK-negative unresectable stage III non-small cell lung cancer

A retrospective comparative cohort study: concurrent versus consolidative immunotherapy with chemoradiotherapy in EGFR- or ALK-negative unresectable stage III non-small cell lung cancer

Therapeutic Implications of PTEN in Non-Small Cell Lung Cancer

EGFR-Targeted Therapies: A Literature Review

Contact Info

Product

Resources

About